Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.75 |
| ▸ | CYP1B1 | Q16678 | 10/20 | 0.72 |
| ▸ | CYP1A1 | P04798 | 9/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.64 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | JUN | P05412 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794941 | 1.00 | RAB9A (0.76) | RAB9AMAPTKMT2APFKFB3CYP1B1 | |
| SCHEMBL13479662 | 0.92 | RAB9A (0.88) | RAB9AMAPTKMT2APFKFB3CYP1B1 | |
| SCHEMBL1604140 | 0.86 | RAB9A (1.00) | RAB9AMAPTKMT2APFKFB3CYP1B1 | |
| SCHEMBL5646960 | 0.86 | RAB9A (1.00) | RAB9AMAPTKMT2APFKFB3CYP1B1 | |
| SCHEMBL29600034 | 0.86 | RAB9A (1.00) | RAB9AMAPTKMT2APFKFB3CYP1B1 | |
| SCHEMBL196639 | 0.86 | PFKFB3 (1.00) | RAB9AMAPTKMT2APFKFB3CYP1B1 | |
| SCHEMBL979409 | 0.86 | CYP1B1 (0.83) | RAB9AMAPTKMT2APFKFB3CYP1B1 | |
| SCHEMBL7368933 | 0.86 | CYP1B1 (0.83) | RAB9AMAPTKMT2APFKFB3CYP1B1 | |
| SCHEMBL29458617 | 0.86 | PFKFB3 (1.00) | RAB9AMAPTKMT2APFKFB3CYP1B1 | |
| SCHEMBL196640 | 0.86 | PFKFB3 (1.00) | RAB9AMAPTKMT2APFKFB3CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-10428029-B2 | Isoxazole carboxamide compounds | Epizyme, Inc. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428029-B2 | Isoxazole carboxamide compounds | Epizyme, Inc. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3193603-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2016040498-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428029-B2 | Isoxazole carboxamide compounds | SMYD3, SMYD2, SNRPD3 | RAB9A 759/4885MAPT 3577/4885KMT2A 580/4885 |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | SMYD3, SMYD2, SNRPD3 | RAB9A 759/4885MAPT 3577/4885KMT2A 580/4885 |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | RAB9A 3707/4885MAPT 4795/4885KMT2A 2457/4885 |
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | SMYD3, SMYD2, SNRPD3 | RAB9A 705/4885MAPT 3503/4885KMT2A 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.